Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

  • Home
  • /
  • Ipca Laboratories
Join Channel
Consolidated Standalone

Ipca Laboratories

₹1592.9 10.6 | 0.7%

Market Cap ₹40411 Cr.

Stock P/E 76.4

P/B 6

Current Price ₹1592.9

Book Value ₹ 264.1

Face Value 1

52W High ₹1708.7

Dividend Yield 0.25%

52W Low ₹ 1053.5

Edit Ratio

Ipca Laboratories Research see more...

Overview Inc. Year: 1949Industry: Pharmaceuticals & Drugs

Ipca Laboratories Ltd is an India-based pharmaceutical company. The Company is in production and marketing over 350 formulations and about 80 APIs masking diverse healing segments. It offers APIs, which includes Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Atenolol, Chloroquine Phosphate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The Company gives brands, consisting of Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Luliz, Ozepam, Pacimol, Pari, Venpower and Folitrax. The merchandise of the Company are sold in over 100 international locations across the globe. The Company has 17 manufacturing devices in India manufacturing API's and formulations. Its subsidiaries consist of Ipca Pharmaceuticals, Inc., USA Ipca Laboratories (U.K.) Ltd and Tonira Exports Ltd.

Read More..

Ipca Laboratories Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Ipca Laboratories Quarterly Results

#(Fig in Cr.) Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 1586 1601 1546 1512 1585 2034 2053 2033 2093 2355
Other Income 22 36 31 36 45 39 22 19 21 26
Total Income 1608 1637 1577 1548 1630 2073 2075 2052 2113 2381
Total Expenditure 1317 1340 1330 1331 1277 1673 1722 1711 1700 1913
Operating Profit 291 297 247 217 353 399 354 341 413 468
Interest 7 9 11 18 31 44 33 29 24 23
Depreciation 62 64 67 70 69 90 100 98 99 100
Exceptional Income / Expenses 0 0 0 0 -0 -39 68 -137 0 0
Profit Before Tax 223 224 169 129 252 225 289 77 290 345
Provision for Tax 74 77 54 48 86 88 66 74 91 99
Profit After Tax 148 147 116 81 166 137 223 3 199 245
Adjustments -5 -3 -8 -5 -3 8 -43 57 -7 -16
Profit After Adjustments 143 144 108 77 163 145 180 60 192 229
Adjusted Earnings Per Share 5.6 5.7 4.3 3 6.4 5.7 7.1 2.3 7.6 9

Ipca Laboratories Profit & Loss

#(Fig in Cr.) Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
Net Sales 3282 3144 2867 3156 3258 3746 4619 5395 5797 6204 7662 8534
Other Income 52 59 41 55 58 75 87 129 122 152 184 88
Total Income 3334 3203 2908 3211 3316 3820 4706 5524 5918 6356 7847 8621
Total Expenditure 2570 2630 2593 2741 2816 3067 3729 3914 4539 5301 6398 7046
Operating Profit 764 573 314 470 500 753 977 1610 1379 1055 1448 1576
Interest 30 32 35 27 28 22 20 12 11 48 141 109
Depreciation 103 180 163 173 178 182 211 209 232 262 357 397
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0 -108 -69
Profit Before Tax 631 361 117 262 291 546 739 1389 1136 745 843 1001
Provision for Tax 152 102 20 68 51 104 135 240 225 253 313 330
Profit After Tax 478 259 96 195 239 442 604 1149 911 492 529 670
Adjustments 0 -5 -3 0 0 3 3 -9 -27 -21 18 -9
Profit After Adjustments 479 254 93 195 239 446 606 1140 884 471 547 661
Adjusted Earnings Per Share 19 10.1 3.7 7.7 9.5 17.6 24 44.9 34.8 18.6 21.6 26

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 24% 12% 15% 9%
Operating Profit CAGR 37% -3% 14% 7%
PAT CAGR 8% -23% 4% 1%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 50% 16% 23% 16%
ROE Average 9% 12% 16% 14%
ROCE Average 13% 15% 19% 16%

Ipca Laboratories Balance Sheet

#(Fig in Cr.) Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Shareholder's Funds 1960 2208 2259 2455 2689 3122 3627 4702 5465 5842 6332
Minority's Interest 0 0 0 0 0 16 14 15 77 73 1395
Borrowings 294 503 484 352 234 141 103 9 395 652 580
Other Non-Current Liabilities 165 196 178 197 185 173 187 181 219 250 434
Total Current Liabilities 791 904 970 956 1008 1098 1326 1161 1466 1806 2356
Total Liabilities 3211 3812 3892 3960 4116 4549 5258 6066 7622 8623 11097
Fixed Assets 1354 1800 2014 1983 1953 1940 2059 2072 2402 2751 4554
Other Non-Current Assets 256 398 256 234 217 231 343 557 762 682 1005
Total Current Assets 1601 1614 1622 1742 1945 2378 2856 3437 4447 5189 5536
Total Assets 3211 3812 3892 3960 4116 4549 5258 6066 7622 8623 11097

Ipca Laboratories Cash Flow

#(Fig in Cr.) Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Opening Cash & Cash Equivalents 57 74 140 169 143 218 371 295 559 991 1579
Cash Flow from Operating Activities 522 468 709 282 341 501 570 1090 856 806 945
Cash Flow from Investing Activities -369 -689 -218 -149 -135 -165 -510 -521 -855 -725 -1292
Cash Flow from Financing Activities -136 251 -462 -159 -130 -183 -137 -306 427 507 -553
Net Cash Inflow / Outflow 17 29 29 -26 75 153 -76 264 428 588 -900
Closing Cash & Cash Equivalent 74 104 169 143 218 371 295 559 991 1579 756

Ipca Laboratories Ratios

# Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Earnings Per Share (Rs) 18.96 10.07 3.69 7.71 9.49 17.63 23.99 44.94 34.85 18.58 21.57
CEPS(Rs) 23.03 17.38 10.28 14.56 16.53 24.72 32.21 53.53 45.07 29.7 34.94
DPS(Rs) 2.5 0.5 0 0.5 0.5 1.5 2.5 4 4 4 4
Book NAV/Share(Rs) 77.64 87.5 89.51 97.28 106.51 123.56 143.08 185.32 215.41 230.27 249.53
Core EBITDA Margin(%) 21.49 16.18 9.42 12.93 13.46 17.98 19.16 27.33 21.57 14.47 16.41
EBIT Margin(%) 19.94 12.38 5.2 9 9.69 15.07 16.32 25.85 19.67 12.71 12.76
Pre Tax Margin(%) 19.03 11.37 4.01 8.16 8.85 14.48 15.89 25.63 19.48 11.94 10.94
PAT Margin (%) 14.43 8.16 3.31 6.06 7.29 11.72 12.98 21.2 15.63 7.88 6.87
Cash Profit Margin (%) 17.54 13.81 8.93 11.44 12.7 16.55 17.51 25.06 19.61 12.07 11.5
ROA(%) 16.19 7.38 2.5 4.96 5.93 10.21 12.31 20.29 13.31 6.06 5.37
ROE(%) 27.22 12.43 4.31 8.25 9.31 15.22 17.92 27.63 17.92 8.7 8.7
ROCE(%) 27.92 13.78 4.82 9.18 9.81 16.48 19.71 30.92 20.46 11.71 13.1
Receivable days 47.78 46.12 50.16 53.75 61.27 62.09 61.9 57.48 53.92 55.52 63.37
Inventory Days 87.49 101.93 110.76 97.7 97.98 94.47 94.05 98.25 108.09 105.25 99.83
Payable days 89.81 105.4 140.86 148.75 138.61 141.38 128.13 136.39 111.16 86.04 100.5
PER(x) 22.28 31.7 78.55 40.44 34.52 27.86 28.93 21.17 30.45 43.62 57.39
Price/Book(x) 5.44 3.65 3.24 3.2 3.07 3.98 4.85 5.13 4.93 3.52 4.96
Dividend Yield(%) 0.59 0.16 0 0.16 0.15 0.31 0.36 0.42 0.38 0.49 0.32
EV/Net Sales(x) 3.41 2.82 2.79 2.71 2.68 3.36 3.86 4.45 4.67 3.25 4.24
EV/Core EBITDA(x) 14.64 15.48 25.47 18.18 17.48 16.73 18.26 14.92 19.63 19.11 22.44
Net Sales Growth(%) 16.96 -4.19 -8.82 10.08 3.22 14.98 23.32 16.8 7.45 7.03 23.5
EBIT Growth(%) 34.66 -40.5 -61.55 91.12 10.08 78.78 33.4 84.7 -18.15 -30.82 23.94
PAT Growth(%) 47.44 -45.81 -62.88 102.22 23.07 84.7 36.48 90.34 -20.71 -46 7.58
EPS Growth(%) 47.9 -46.87 -63.36 108.87 23.07 85.89 36.07 87.28 -22.45 -46.69 16.13
Debt/Equity(x) 0.31 0.42 0.38 0.29 0.23 0.15 0.13 0.05 0.14 0.25 0.22
Current Ratio(x) 2.02 1.78 1.67 1.82 1.93 2.17 2.15 2.96 3.03 2.87 2.35
Quick Ratio(x) 0.95 0.76 0.81 0.9 1.06 1.19 1.16 1.59 1.77 1.91 1.3
Interest Cover(x) 21.86 12.24 4.38 10.74 11.54 25.57 38.37 114.2 102.4 16.47 6.99
Total Debt/Mcap(x) 0.06 0.12 0.12 0.09 0.08 0.04 0.03 0.01 0.03 0.07 0.04

Ipca Laboratories Shareholding Pattern

# Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Promoter 46.29 46.29 46.29 46.29 46.29 46.29 46.29 46.3 46.3 46.3
FII 10.61 10.55 10.44 10.57 10.05 9.85 10.27 10.5 10.85 10.83
DII 33.74 33.81 34.04 34.07 35.19 35.05 34.52 34.37 33.78 34.22
Public 9.37 9.35 9.22 9.07 8.48 8.81 8.92 8.82 9.07 8.65
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Promoter holding is low: 46.3%.
  • Company has a low return on equity of 12% over the last 3 years.
  • Debtor days have increased from 86.04 to 100.5days.
  • Stock is trading at 6 times its book value.
  • The company has delivered a poor profit growth of 3% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Ipca Laboratories News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!